Sironax
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $200M
Overview
Develops senolytic and regenerative therapies for age-related diseases in ophthalmology and neurology.
OphthalmologyNeuroscienceRegenerative Medicine
Technology Platform
A discovery platform focused on identifying compounds that selectively target senescent cells or modulate regenerative pathways to treat age-related dysfunction.
Funding History
1Total raised:$200M
Series B$200M
Opportunities
Large, underserved aging population with diseases lacking disease-modifying treatments provides a substantial market opportunity.
Risk Factors
Unproven clinical validation for senolytic therapies and potential challenges in demonstrating clear efficacy endpoints in complex age-related diseases.
Competitive Landscape
Competes with other senolytic-focused companies like Unity Biotechnology and Life Biosciences in the emerging field of targeting aging biology for therapeutic gain.